Get the Stockscreener App
12.60
2.14%
-0.275
After Hours:
12.84
0.245
+1.95%
Phathom Pharmaceuticals Inc stock is traded at $12.60, with a volume of 1.09M.
It is down -2.14% in the last 24 hours and up +11.07% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$12.87
Open:
$12.87
24h Volume:
1.09M
Relative Volume:
0.92
Market Cap:
$1.00B
Revenue:
$204.89M
Net Income/Loss:
$-157.30M
P/E Ratio:
-5.9661
EPS:
-2.1111
Net Cash Flow:
$-97.76M
1W Performance:
+11.17%
1M Performance:
+11.07%
6M Performance:
-5.16%
1Y Performance:
+388.18%
1-Day Range:
$12.21
$12.95
1-Week Range:
$9.735
$13.00
52-Week Range:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
12.60 | 1.03B | 204.89M | -157.30M | -97.76M | -2.1111 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-12-25 | Initiated | Raymond James | Strong Buy |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Phathom Pharmaceuticals CEO drives new momentum after DDW2026 to advance GI patient care - Traders Union
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline - Yahoo Finance
Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3 - MSN
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - Stock Traders Daily
147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc. - MarketBeat
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX) - The Globe and Mail
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call - The Globe and Mail
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5%Should You Buy? - MarketBeat
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28 - Moomoo
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals announces DDW2026 booth and team participation in Chicago - Traders Union
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - The Manila Times
GERD drug VOQUEZNA gets 3 posters and a May 4 presentation at DDW - Stock Titan
Phathom Pharmaceuticals Inc (PHAT) Q1 2026 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Phathom Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-04-30 - Seeking Alpha
Phathom Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) reports Q1 loss, tops revenue estimates - MSN
Phathom (PHAT) Q1 2026 Earnings Transcript - The Globe and Mail
Phathom Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Reports Q1 2026 Results: VOQUEZNA Prescriptions Surge, Revenue Doubles, Operating Profitability Expected in Q3 - Minichart
Phathom Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings Miss - MarketBeat
Earnings call transcript: Phathom Pharmaceuticals beats EPS expectations in Q1 2026 By Investing.com - Investing.com South Africa
Is Phathom Pharmaceuticals (PHAT) Fairly Valued After Q1 2026 Ea - GuruFocus
Earnings call transcript: Phathom Pharmaceuticals beats EPS expectations in Q1 2026 - Investing.com
Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Q1 2026 Phathom Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Reports Q1 Product Revenue $58.3M, vs. FactSet Est of $55.9M - marketscreener.com
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q1 Adjusted Loss $0.18 per Share, vs. FactSet Est of $-0.21 - marketscreener.com
Phathom Pharmaceuticals Q1 2026 earnings preview - MSN
8-K: Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Phathom Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Phathom Pharmaceuticals reports Q1 2026 revenue $58.3M, narrows net loss to $30.4M - TradingView
1.35M VOQUEZNA prescriptions filled; Phathom expects Q3 operating profitability - Stock Titan
VOQUEZNA growth moves Phathom (NASDAQ: PHAT) closer to profitability - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) doubles Q1 2026 revenue, cuts loss - Stock Titan
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - ChartMill
Phathom Q1 2026 slides: revenue doubles, profitability in sight By Investing.com - Investing.com Canada
Phathom upgraded at Barclays following pullback, Voquezna optimism - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH) - The Globe and Mail
Phathom Pharmaceuticals Inc (PHAT) Q1 2026: Everything You Need To Know Ahead Of Earnings - GuruFocus
Phathom Pharmaceuticals to present VOQUEZNA clinical data at DDW2026 event - Traders Union
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating - Moomoo
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet - MSN
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):